Immuneering Corp (IMRX)

Every figure below is the company's own, as filed. Nothing is estimated and nothing is smoothed — a period the filing does not support is left blank rather than drawn. Quarters are the company's own, counted from its financial year ending 12-31. Amounts in USD.

Revenue Quarterly

0 300K 600K 900K Q1 '20: 483.1K Q2 '20: 480.8K Q3 '20: 682.6K Q4 '20: 665.1K Q1 '21: 748.2K Q2 '21: 660K Q3 '21: 482.1K Q4 '21: 189.6K Q1 '22: 183.7K Q2 '22: 94.4K Q3 '22: 38.4K Q4 '22: 455 Q1 '23: 0 Q2 '23: 0 Q3 '23: 0 Q4 '23: 0 Q2 '20 Q4 '20 Q2 '21 Q4 '21 Q2 '22 Q4 '22 Q2 '23 Q4 '23

Gross Profit Quarterly

-150K 0 150K 300K 450K Q1 '20: 228K Q2 '20: 243.8K Q3 '20: 367.6K Q4 '20: 191.8K Q1 '21: 339K Q2 '21: 341.4K Q3 '21: 263K Q4 '21: -16.6K Q1 '22: 92.9K Q2 '22: 46.5K Q3 '22: 19K Q4 '22: 455 Q1 '23: 0 Q2 '23: 0 Q3 '23: 0 Q4 '23: 0 Q2 '20 Q4 '20 Q2 '21 Q4 '21 Q2 '22 Q4 '22 Q2 '23 Q4 '23

Operating Income Quarterly

-21M -14M -7M 0 7M 14M 21M Q3 '21: -8.5M Q4 '21: -11.1M Q1 '22: -12.9M Q2 '22: -11.6M Q3 '22: -13.2M Q4 '22: -14M Q1 '23: -14.7M Q2 '23: -13.5M Q3 '23: -13.9M Q4 '23: -16.3M Q1 '24: -15.3M Q2 '24: -14.9M Q3 '24: -15.3M Q4 '24: -18.6M Q1 '25: -15.5M Q2 '25: -14.8M Q3 '25: -15.4M Q4 '25: -13.8M Q1 '26: -15.3M Q2 '26: -19M Q4 '21 Q3 '22 Q2 '23 Q1 '24 Q4 '24 Q3 '25 Q2 '26

Net Income Quarterly

-21M -14M -7M 0 7M 14M 21M Q3 '21: -8.5M Q4 '21: -10.8M Q1 '22: -12.9M Q2 '22: -11.5M Q3 '22: -12.8M Q4 '22: -13.2M Q1 '23: -13.6M Q2 '23: -12.2M Q3 '23: -12.6M Q4 '23: -15.1M Q1 '24: -14.3M Q2 '24: -14.1M Q3 '24: -14.6M Q4 '24: -18.1M Q1 '25: -15M Q2 '25: -14.4M Q3 '25: -15M Q4 '25: -11.6M Q1 '26: -13.5M Q2 '26: -17.3M Q4 '21 Q3 '22 Q2 '23 Q1 '24 Q4 '24 Q3 '25 Q2 '26

Cost of Revenue Quarterly

0 200K 400K 600K Q1 '20: 255K Q2 '20: 237.1K Q3 '20: 315K Q4 '20: 473.2K Q1 '21: 409.2K Q2 '21: 318.6K Q3 '21: 219.1K Q4 '21: 206.2K Q1 '22: 90.8K Q2 '22: 47.9K Q3 '22: 19.3K Q4 '22: 0 Q1 '23: 0 Q2 '23: 0 Q3 '23: 0 Q4 '23: 0 Q2 '20 Q4 '20 Q2 '21 Q4 '21 Q2 '22 Q4 '22 Q2 '23 Q4 '23

Operating Cash Flow Quarterly

-21M -14M -7M 0 7M 14M 21M Q3 '21: -9M Q4 '21: -9.2M Q1 '22: -12.3M Q2 '22: -9.4M Q3 '22: -10.6M Q4 '22: -11.7M Q1 '23: -14.4M Q2 '23: -10.7M Q3 '23: -12M Q4 '23: -11.8M Q1 '24: -15.5M Q2 '24: -11.5M Q3 '24: -13.5M Q4 '24: -14.5M Q1 '25: -14.1M Q2 '25: -9.4M Q3 '25: -12M Q4 '25: -9.8M Q1 '26: -18.4M Q2 '26: -16.5M Q4 '21 Q3 '22 Q2 '23 Q1 '24 Q4 '24 Q3 '25 Q2 '26

Free Cash Flow Quarterly

-21M -14M -7M 0 7M 14M 21M Q3 '21: -9M Q4 '21: -9.3M Q1 '22: -12.4M Q2 '22: -9.6M Q3 '22: -11M Q4 '22: -11.8M Q1 '23: -14.4M Q2 '23: -10.8M Q3 '23: -12.1M Q4 '23: -11.9M Q1 '24: -15.5M Q2 '24: -11.6M Q3 '24: -13.5M Q4 '24: -14.5M Q1 '25: -14.1M Q2 '25: -9.4M Q3 '25: -12M Q4 '25: -10M Q1 '26: -18.5M Q2 '26: -16.5M Q4 '21 Q3 '22 Q2 '23 Q1 '24 Q4 '24 Q3 '25 Q2 '26

Operating cash flow minus capital expenditure.

Shares Outstanding Quarterly

0 25M 50M 75M Q2 '20: 5M Q3 '20: 5M Q1 '21: 5M Q2 '21: 5M Q3 '21: 18.3M Q1 '22: 26.4M Q2 '22: 26.4M Q3 '22: 26.4M Q1 '23: 26.4M Q2 '23: 28.6M Q3 '23: 29.3M Q1 '24: 29.4M Q2 '24: 29.7M Q3 '24: 29.8M Q1 '25: 35.5M Q2 '25: 36M Q3 '25: 39.7M Q1 '26: 64.7M Q2 '26: 64.7M Q2 '20 Q2 '21 Q2 '22 Q2 '23 Q2 '24 Q2 '25 Q2 '26

Weighted average diluted, as the filer reports it for each period. An average cannot be added across periods, so this one is always shown per period the filer tagged rather than as a trailing year.

EPS TTM

-6.00 -4.00 -2.00 0.00 2.00 4.00 6.00 Q3 '21: -4.52 Q4 '21: -2.46 Q1 '22: -1.69 Q2 '22: -0.52 Q3 '22: -0.54 Q4 '22: -1.92 Q1 '23: -1.94 Q2 '23: -1.93 Q3 '23: -1.87 Q4 '23: -1.89 Q1 '24: -1.87 Q2 '24: -1.91 Q3 '24: -1.97 Q4 '24: -2.04 Q1 '25: -1.97 Q2 '25: -1.90 Q3 '25: -1.79 Q4 '25: -1.27 Q1 '26: -1.06 Q2 '26: -0.93 Q4 '21 Q3 '22 Q2 '23 Q1 '24 Q4 '24 Q3 '25 Q2 '26

The filer's own published earnings a share for each quarter, four quarters added up. The company page divides trailing net income by the share count instead, which lands within about 1% of this and is not the same sum, so the two are named differently rather than presented as one figure.